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ABSTRACT 
 
Diffuse Large B Cell Lymphoma is one of the most common Non-Hodgkin’s Lymphomas. It 
is prevalent in older age patients but as of late there has been a rise in the younger population 
in South Africa due to the rise of HIV. DLBCL is quite an aggressive cancer but can be 
treated, however the relapse rate is high. There are prognostic indicators which can be seen as 
factors which can be indicative of a poor outcome for patients.  
Micro-RNA(miRNA) are small non-coding RNA which can remain stable to be tested. There 
are several miRNAs which may be linked to prognosis, including miRNA-21 whose 
upregulated expression has been associated with bad prognosis. However, this is not specific 
to DLBCL and some studies done have indicated that there may be other miRNAs which are 
better suited to be biomarkers for DLBCL. Studies have pointed to the direction of miRNA-
127 as a more reliable microRNA in its association with prognosis in breast, cervical and 
gastric cancer as well as DLBCL.  
Objective: The primary aim of this study was to determine the association between miRNA-
127 and prognostic markers including immunohistochemical stains, survival status and the 
IPI factor to determine its significance as a prognostic indicator. An additional aim was to 
determine the correlation between HIV status and expression level of miRNA-127.  
Design: A total of 42 DLBCL cases were collected from the archive of Division of 
Anatomical Pathology, University of Cape Town/NHLS Groote Schuur. The H&E slides 
were assessed before RNA was extracted from FFPE tissue and converted to cDNA. Real 
time quantitative RT-qPCR was used to assess the expression of the microRNA. Normal 
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tissue as well as reactive lymph node tissue were used as controls. The expression patterns 
were also correlated to the clinical information to determine if there was any relationship.  
Results: Out of the 42 cases used, 10 cases were silenced, and 31 cases had high miRNA-127 
expression. The expression levels were correlated with the IPI factors and the other 
clinicopathologic features however no significant conclusion were determined.  
Conclusion: We found high expression of miRNA-127 cases in the majority of the DLBCL 
cases. There was no correlation between HIV status and the expression of miRNA-127, nor 
between the expression and any of the clinicopathological feature. For future studies it is 
advised that more equally distribution of samples (both HIV status and gender) are obtained, 
this will allow for a better comparative study.  
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MicroRNA are small non-coding RNA that post transcriptionally regulate gene expression 
and are derived from genome encoded stem loop precursors. They function through TNA 
induced silencing complex (RISC) mediated binding to target mRNA by pairing to the 3’ 
untranslated region. MiRNA have been associated with many cancers and because of the 
stability in some bodily fluid may help diagnostic testing.  
 
One of the most common lymphomas is Diffuse Large B-Cell lymphoma (DLBCL). This 
cancer is curable but if left untreated can lead to death in a short time span and although 
curable DLBCL has a high relapse rate. With the rise of HIV in South Africa there has been a 
rise of DLBCL cases, not only in adults but there has also been in a rise in younger patients.  
 
The purpose of this study was to determine the expression levels of miRNA-127 and 
investigate the prognostic value it may hold in Diffuse Large B-cell Lymphoma (DLBCL).  
A quantitative reverse transcription PCR will be performed to detect miRNA-127 expression 
in the cohort and correlated it with the clinicopathological factors. The study will also 
investigate whether the miRNA-127 expression levels between a cohort of HIV positive and 
HIV negative patients differ.  
 
In many cancers miRNA-127 has been reported to be significantly downregulated, where low 
levels are also associated with advanced clinical stage and metastases. Lower miRNA-127 
was therefore indicative of a poor prognosis. Therefore miRNA-127 may be a potential 
biomarker for predicting survival of patients with DLBCL. No literature has investigated the 
relationship between miRNA-127 expression and HIV status, and it is hypothesised that with 
a higher CD4 count miRNA-127 expression may be lower.  
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2.1 Cancer 
 
It has been estimated that in 2018, 18.1 million new cases and 9.6 million cancer deaths will 
be reported worldwide.121 This estimate shows a big increase in the figures estimated in 2012, 
where new cancer cases were an estimated 14.2 million and 8.2 million cancer-related deaths, 
were reported worldwide.1 According to the 2002 Revised Burden of disease estimates in South 
Africa, lymphoma was the 12th most common cancer, with lymphoma related deaths ranking 
at 2.5% with 1032 deaths, of which 601 were males. According to the National Health 
Laboratory Services (NHLS) Cancer Registry2 in 2011, 804 new Non-Hodgkin’s Lymphomas 
cases were reported in males and 712 in new female patients. The highest prevalence for males 
was in the 40-44-year age group and the 35-39-year age group for women. 
 
Cancer is a genetic disease characterised by the uncontrollable proliferation and evasion of cell 
death of damaged cells.3 Cancer cells can invade the entire body by moving through the 
basement membrane into the blood and lymphatics vessles.  A study by Stephens and Aigner 
showed that a single cell with 6-12 mutations is believed to cause cancer. There are a number 
of factors that cause damage to the genetic blueprint, thus resulting in mutations.4 Mutations in 
the genes that encode for proto-oncogenes and tumour suppressors can lead to the gene 
becoming activate or inactivate.16 Many factors may cause epigenetic or genetic changes which 
can lead to the development of cancer.76 
 
Cancer is distinguished by the type of cell and where it originates from, with the cells being 
classified according to their appearance. Cancers are named according to the cells of which 
they are composed, e.g.; epithelial malignancies are carcinomas, connective tissue 
malignancies are sarcomas and lymphocyte malignancies are lymphomas.   
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2.1.1 Carcinogenesis 
 
Carcinogenesis is the development of cancer from normal cells to a cancerous cell. There are 
three steps in carcinogenesis: tumour initiation, promotion and progression illustrated in figure 
1, below. Tumour initiation occurs when there is an interaction between the carcinogen and the 
cell DNA. This may cause a break or damage to occur in the DNA strand. If the damage is 
repaired, no initiation step will take place. In the promotion step, the damaged cell multiplies, 
causing the damaged genome to be replicated. Progression, the irreversible step, is where there 
is further growth of mutated cells followed by angiogenesis, allowing the cells to grow. Once 
cancerous cells cross the basement membrane they are able to metastasize to other parts of the 
body.16  
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Figure 1: Carcinogenesis stages. When a cell is damaged it will either be repaired or if it 
cannot be repaired the cell will undergo apoptosis. However, a cell may undergo a mutation 
where it is unable to undergo apoptosis and neither repair itself, and this is the start of the 
development of cancer. The cell with the mutated gene will then divide and duplicate forming 
more cells with the mutation leading to promotion of the cancer cell and later progression. 74  
 
2.1.2 Aetiology/Epidemiology 
 
There are a number of factors that may increase the risk of developing cancer. They include 
tobacco, alcohol use, certain infectious agents, radiation, poor  nutrition, certain gynaecological 
and environmental factors6.  The International Agency for Research on Cancer (IARC)7 has 
developed a classification system based on the carcinogenic relationship in humans - Group 1 
comprises agents that are carcinogenic to humans; Group 2 is divided into two subtypes: 2A 
which is probably carcinogenic to humans (limited human carcinogenic evidence but sufficient 
animal carcinogenic relationship) and subtype 2B comprising possibly carcinogenic to humans 
(limited human evidence, and not sufficient animal evidence); Group 3 comprise not 
classifiable agents, and Group 4  which is probably not carcinogenic to humans.8  
 
2.1.2.1 Tobacco and alcohol use 
 
According to WHO, tobacco in any form (snuff, cigarettes, pipe smoking) is the cause of 20% 
of cancer deaths worldwide, as well as 70% of lung cancer. Whilst tobacco can cause lung, 
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oesophageal or mouth cancer, alcohol consumption can increase the chances of development 
of cancers, especially cancers affecting the liver, colon and even the female breast. According 
to IARC both are Group 1 carcinogens.9  
 
2.1.2.2 Diet and poor nutrition 
 
Poor diet plays a role in the development of cancer. The lack of essential vitamins needed for 
cell development or even the absence of proper proteins may result in the body not being 
properly protected or having the required amino acids, therefore, causing mutations which may 
lead to cancer development. This may not have a direct effect but may have a ripple effect. 
With mass production of food, more hormone additives that may lead to hormonal imbalance 
are being consumed, and may lead to cancer.  
 
A high obesity rate has been correlated with a higher risk of cancer development in adults, 
seeing an increase of development of endometrial cancer in women, but also cancer of the 
kidneys, gallbladder or the colon in men.6. Obesity may also affect prognosis and survival. 
Certain foods have a carcinogenic effect, for example, salty fish (Chinese-style) and processed 
meat like bacon and salami are Group 1 carcinogens according to IARC and are linked to 
causing nasopharynx and stomach cancer.9 
 
2.1.2.3 Infection  
 
There are several infectious organisms that play a role in the development of cancer. They are 
responsible for 15% of cancers deaths. These infectious organisms include viruses, parasites 
and bacteria and are all Group 1 carcinogens according to IARC.9. Viral infection including 
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Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), Hepatitis B and C, 
Human T-cell lymphotropic virus type 1 (HTLV-1), Epstein-Barr virus and Human Herpes 
virus (HHV-8). Helicobacter pylori and Chlamydia trachomatous are bacterial infections 
whereas Schistosoma haematobium, Opisthorchis viverrine and Clonorchis Sinensis are 
parasitic agents.  HPV, which is commonly linked to cervical cancer and Epstein–Barr virus, 
is commonly linked to lymphomas.6   
 
2.1.2.4 Radiation 
 
Radiation causes 2% of cancer deaths. Forms of radiation may include sun rays (UV radiation), 
X-rays, cellphones (radiofrequency waves) or appliances like microwaves. Naturally occurring 
radon gas may also be hazardous.6  
 
2.1.2.5 Environmental factors and occupational hazard 
 
With the growth of cities and urbanisation, pollution and deforestation greatly affect the 
environment and people. Pollution and water contamination are some of the main side effects 
that may contribute to the development of cancer. Water contaminants may lead to a variety of 
cancers, for example, pesticide contamination has been suspected to lead to Non-Hodgkin’s 
lymphoma. Water disinfectant by-products have also been found to lead to certain cancers, 
including bladder and colorectal cancer, which may be due to the chlorination.  
 
There are other hazards in the working environment that may have a small contribution to the 
development of cancer. For example, hairdressers who work with hair dye tend to get bladder 
cancer. There are other factors which are more commonly noted to cause damage, like working 
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with asbestos that may lead to mesothelioma or even lung cancer, similar to railway workers 
who inhale diesel fumes.6 
 
2.1.2.6 Gynaecologic Factors 
 
Hormones may play an important part in the development of cancers. Menstrual cycles, the age 
of initial pregnancy or onset of menopause may all be an indication of the risk of development 
of cancer.  
 
According to Trichopoulos et al., an increase in the number of pregnancies in women may 
contribute to a lower risk of development of cancer of the endometrium, ovary or breast.6 
 
 
 
 
 
Gynaecological factor Period more inclined to cause 
cancer 
Cancer that tends to develop 
Menstrual cycle Under 13 Breast cancer 
First pregnancy Over 35 Breast cancer 
Menopause Over 60 Breast cancer 
Table 1: Age of onset of certain gynaecological factors governed mainly by hormones may be 
an indication of which cancer is inclined to develop.6  
 22 
 
2.1.2.7 Hereditary factors and age 
 
Genetic defects play a significant role in the development of cancer. If a family has a mutated 
gene or is prone to mutation of a gene, these genes may be inherited.6 Inherited mutations are 
present in the first cells formed, the mutation may be present in either the egg or the sperm. 
Therefore, inherited cancers may start developing from an early age, but some may require 
certain mutations to occur for cancer to be present.10. With age, the incidence of cancer tends to 
increase, which may be attributed to accumulations of mutations over the years.5  
 
2.1.3 Epigenetic Regulation 
 
Environmental stresses increase genomic instability which can lead to genes undergoing 
epigenetic regulation. Epigenetic refers to all heritable changes not coded in the DNA sequence 
but in gene expression and chromatin structure. Epigenetic mechanisms may include either the 
addition of the methyl group to the promotor region of the gene or histone modification which 
allow for stable propagation of gene activity but when these processes are disrupted it may lead 
to tumorigenesis .73 Figure 2. illustrates the initiation phase of cancer. Here, DNA is damaged 
due to a variety of factors that may cause different types of mutations to occur. It is seen that 
the damage caused may lead to either somatic or epigenetic alterations if DNA damage is not 
repaired. Germ line mutations can also occur which can affect the DNA repair genes. The DNA 
damage that leads to epigenetic alterations can then be classified into histone modification or 
CpG island methylation. 11 
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 In the case of histone modification, histones may become more tightly wound, making certain 
DNA inaccessible, or may have a non-histone protein binding to the histone tail, thus decoding 
the message.  
 
With DNA methylation, the methyl groups may join to CpG island which result in 
transcriptional silencing (seen in tumour suppresor genes) or a methyl group may be removed 
(normally seen in oncogenes) 75. Figure 3. illustrates DNA methylation, where on the left side, 
it represents hypomethylation, a methyl group is removed, and on the right side, 
Figure 2: Initiation of cancer from the initial influence of the risk factors.11  
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hypermethylation is shown where a methyl group is added to the CpG island. The CpG island 
is a short stretch of DNA where the frequency of C-G sequence is higher than others. In the 
case of miRNA genes, they too can undergo epigenetic alterations. This will then result in the 
miRNA expression being deregulated, causing overexpression or underexpression of certain 
genes. For instance, RET may be overexpressed due to increased level of the miRNA, causing 
increased growth.11, 12, 13 CpG island methylation is emerging as a common hallmark of a variety 
of tumours according to Guo et al.14  
 
 
Figure 3: DNA Methylation15  
 
Phenotypic changes occur due to alternations in the genes. The abnormalities can affect two 
classes of genes, the tumour suppressor genes and the oncogenes. There are a variety of both 
classes of genes that target different areas and functions.16  
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2.1.3.1 Oncogenes 
Proto-oncogenes play an important role in cellular growth and proliferation.71 When proto-
oncogenes mutate to become permanently activated, they are called oncogenes. Oncogenes are 
classified into six main groups: transcription factors, tyrosine kinase, growth factors, receptor 
tyrosine kinase, regulatory GTPase, and serine or threonine kinases.17 
They are involved in organism development, including activation of the receptors for cell 
proliferation, inducing cell proliferation, transducing signals  for cell growth, regulating 
transcription and apoptosis.  
 
2.1.3.2 Tumour suppressors genes 
When functioning normally, these are genes that help slow cell division, repair DNA damage 
or initiate apoptosis. Kinzler and Vogelstein18 have classified these genes according to the 
function, grouping them as caretakers, gatekeepers and landscapers. Gatekeepers refer to 
tumour suppressors which control growth by regulating cell cycle and inducing apoptosis; 
caretakers are DNA repair proteins which prevent genetic instability; and landscapers, which 
are the least well characterised, normally regulate tissue morphogenesis and intercellular 
signalling.16 Therefore, when a mutation occurs that cause the tumour suppressor gene to be 
inactivated, it may lead to the formation and progression of cancer. For tumour suppressor 
genes to be inactivated both gene copies are required to be inactivated, this mechanism is 
referred to as the Knudson “two” hit hypothesis.71 
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Figure 4, by Weinberg19, displays a number of oncogenes and tumour suppressors that are 
commonly involved in cancer. Here Weinberg illustrates that whether a tumour suppressor or 
an oncogene, in different cancers they work on different areas of the cells or pathways.   
 
 
 
 
 
 
 
 
 
 
 
Depending on the gene that has mutated, the cancer may progress faster or slower. The reason 
for this is each gene plays a different part in the normal pathways, and once one is either 
silenced or overexpressed it will have a direct effect on all systems in the pathway.  
Figure 4: Key genes involved in the development of cancer. Both oncogenes and 
tumour suppressor play different roles .19 
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A mutation initially occurs in one cell, but if that cell does not undergo apoptosis or DNA repair 
the mutated cell will divide. When mutations occur in genes that regulate the cell cycle, this 
may lead to increased cell division. This rapid growth may lead to a mutation of the initial 
mutation which is referred to as a variant of the mutation. This may then lead to a different 
gene being affect hence leading to different people having the same cancer, have may have 
different gene involvement and hence different prognosis. 16 
 
2.1.4 Hallmarks of cancer 
Cancer cells have certain acquired characteristics that are a result of their changes. These six 
hallmarks are referred to as the hallmarks of cancer25 
1. Evading apoptosis 
Apoptosis is the process of programmed cell death. It is needed to ensure there is 
proper division and development of cells. Cancer cells are able to evade this process; 
therefore, cancer cells are not broken up.  
 
2. Inducing angiogenesis 
All cells require nutrients and oxygen to survive which is required from blood vessels. 
Cancers cells can induce new blood vessels to be formed which is referred to as 
angiogenesis.  
 
3. Evading growth suppressors 
Cancer cells are able to evade signals that suppress cell proliferation.  
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4. Activate tissue invasion 
Cancer cells are able to dissociate from primary tumor site and migrate through the 
tissue. They can move through the basement membrane into the blood vessels and 
travel through the blood stream, until they adhere and invade a new area.  
 
5. Limitless replicative potential 
Senescence is referred to the point where after a normal cell enters a stage of 
permanent growth arrest and they can no longer replicate. Cancer cells are able to 
disrupt the telomerase mechanism allowing them to have limitless replicative 
potential. 
 
6. Self-sufficient growth 
The cancer cell produces growth factor so that they are able to be self-reliant and 
sustain constant proliferation.  
 
 
 
 
 
 
 
Figure 5: The hallmarks of cancer.25  
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2.2 MiRNA 
 
2.2.1 MicroRNA biogenesis and function 
 
2.2.1.1 Function 
 
MiRNAs are short single-stranded ribonucleic acid (RNA), which regulate gene expression. 
They can anneal to messenger RNA(mRNA) and, therefore, affect translation of proteins.20. 
MiRNA regulate genes by binding to 3’ untranslated regions of the targeted gene.21 MiRNA 
can regulate expression of 30-60% of protein-coding sequences and, therefore, plays a role in 
the development, differentiation, cell proliferation, cell stress response and apoptosis.22. 
 
MiRNAs are stable in not only body fluids but also in fresh and archived tissue. It can be 
extracted and therefore measured non-invasively.64 65 They been found to have prognostic and 
diagnostic value, where profiling panels have been established to assist in profiling cancers.21 
 
2.2.1.2 Biogenesis  
 
 Figure 6 illustrates the biogenesis of miRNA. This process starts from the intron of the DNA 
and move out into the cytoplasm to silence proteins.23 Each gene is transcribed by RNA 
polymerase II, thus producing a regulatory RNA. This transcript is a primary microRNA and 
can fold into a hairpin structure. DGCR8 (DiGeorge syndrome chromosomal region 8) 
recognises the structure and its associated enzyme, Drosha, then interacts to form a processing 
complex, thus helping to cut it into a smaller miRNA that is able to be transported into the 
cytoplasm. Exportin 5 is then able to transport the miRNA into the cytoplasm where the 
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enzyme DICER, is able to recognise and cut the loop. The remaining double strand RNA 
molecule and DICER then interact with AGO 2, causing the double strand to unwind leaving 
only one strand. The strand with AGO 2 is able to form the RNA Induced Silencing Complex 
(RISC). RISC binds to messenger RNA (mRNA), where it either cuts the mRNA strand or 
binds so that the strand cannot be read, thus leading to silencing of protein encoded by the 
mRNA.24  
 
 
 
 
 
 
 
 
 
Figure 6:  Biogenesis of miRNA.23  
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2.2.2 MicroRNA in cancer 
 
Meola22 investigated the role of miRNA in a variety of diseases and suggested that miRNA may 
contain the mutations that lead to the genetic conditions. miRNA target mRNA which lead to 
either the expression or suppression of proteins, but in cancer the miRNAs expression is 
affected hence leading to protein expression being affected. In some cancers, miRNAs that 
would normally target oncogenic transcripts and therefore supress oncogenic transformation, 
are downregulated, these are known as tumour suppressor miRNAs. Oncogenic miRNAs 
promoting development of cancer are upregulated.26  
 
MiRNAs that have high expressions levels are known as oncomiRs. These oncogenic miRNAs 
are upregulated in certain cancers; miRNA-21 and miRNA-155 are examples of oncomiRs 
leading to high expression of target genes. miRNA-127 is an example of a tumour suppressor. 
These miRNAs have an inverse relationship with their target genes; low miRNA expression is 
associated with high gene expression.13, 39 
 
The location of the miRNAs dictates whether the miRNA may be transcribed singularly 
directly from its promoter or in clusters from a shared promoter. These miRNAs may be 
exonic (found in exons of a gene), intronic (located in the intron) or intergenic (found in 
between genes). 37 
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2.2.2.1 MicroRNA-127  
 
According to Malumbres19 miRNA-127 was the first microRNA found to be epigenetically 
regulated, where miRNA-127 is hypermethylated in tumour cells.19 MiRNA-127 is located on 
chromosome 14q32.231, where it overlaps with miRNA-433 on the 3’ end. It targets BCL6, 
which is involved in apoptosis and DNA damage response.31,32 The primary miRNA(pri-
miRNA) that is transcribed explained in the biogenesis of miRNA (figure 6), can fold into a 
hairpin and they're then processed into pre-miRNA. These structures are transported into the 
cytoplasm to further development into the secondary structures. The structure illustrated below 
is the secondary structure of miRNA-127. 23, 33 
 
Figure 7: Secondary Structure of miRNA-127. 33 
 
2.2.2.1.1 MicroRNA-127 in cancer 
 
In a study by Wang et al.,30 decreased expression levels of miRNA-127 play a very important 
part in breast cancer progression. Low expressions levels have been associated with a decreased 
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overall survival and increased lymph node metastasizes. In this study, miRNA-127 was 
administered and this upregulation saw the reduction of colony formation, enhanced apoptosis 
and suppression of the growth of cells.30  
 
The study by Lee et al.,35 found that miRNAs were associated with prognostic factors and 
disease progression. They found that miRNA deregulation is detectable in the early stages of 
cervical cancer and that miRNA-127 was significantly associated in cases with lymph node 
involvement.35  
 
In gastric cancer, lower expression of miR-127 has been associated with higher grade tumours.14  
 
Roehle et al.,27 carried out a study which looked at the expression signatures of 58 miRNAs in 
Diffuse Large B-Cell Lymphoma (DLBCL). A correlation between miRNA expression and 
survival (event-free and overall) was done. From the 58 miRNAs tested, a panel of 16 miRNAs 
had a p-value of <0.1. Eight of the 16 miRNAs had a significant correlation with overall 
survival (p-value <0.05). Of the eight miRNAs, miRNA-127 was the only miRNA that had 
both overall survival and event-free survival (p<0.05).27 Although miRNA-127 is not highly 
expressed, the expression of this miRNA still has prognostic value as low expression levels are 
indicative of a poor prognosis in DLBCL.27  
 
Low levels of miRNA-127 and high levels of BCL6 give the DLBCL cells proliferative 
advantage as B-cells keep proliferating in the GC centres.36 In DLBCL, miRNA-127 has a low 
expression and is linked to poor prognosis.27, 37  
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2.3 Lymph Nodes and Lymphomas 
 
2.3.1 Lymph Node Anatomy and Histology 
 
The lymphatic system is part of the immune system. Its function is to filter and remove excess 
fluid and waste particles including excess fats, and to defend the body against disease. The 
lymphatic system is divided into two parts, primary lymphoid organs where B and T cells are 
formed and mature, and the secondary lymphoid organs where B and T cell further differentiate 
and are activated.38 The primary lymphoid organs are the bone marrow and thymus, whereas 
the secondary group consists of the lymph, lymph nodes, tonsils, spleen, Peyer’s patch and 
mucosa-associated lymphoid tissue.39  
 
The lymph nodes are small, encapsulated nodes situated throughout the body along the 
lymphatic vessels.40 Lymph nodes can be found in a variety of areas in the body as shown in 
Figure 8. The cervical lymph nodes drain the head and neck, whereas the axillary nodes drain 
the upper limbs down to the umbilicus and the inguinal lymph nodes drain the abdomen below 
the umbilicus and the lower limbs.41  
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The unfiltered lymph enters throughout the afferent vessels and once filtered with the help of 
lymphocytes it is expelled back into the circulation via efferent vessels.39 The lymph node is 
made up of four layers: the capsule and the inner and outer cortex and the medulla. The capsule 
is composed of connective tissue and ensures that the lymph node is protected. The outer cortex 
contains germinal centres which are sites where mature B lymphocytes not only proliferate and 
differentiate, but here antibodies also switch class as part of an immune response.38  
 
 
Figure 8: There are a number of lymph nodes across the body29  
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Figure 9: A schematic view of the lymph node along with the microscopic picture (H&E 
stained) demonstrating the different regions in the lymph node. The lymph enters the lymph 
node through the afferent lymphatic vessel and the filtered lymph leave via the efferent 
lymphatic vessels. The cortex which on presentation of an antigen can develop into a germinal 
centre consists mainly of B cells, where plasma cells and B cells are the central region and the 
medulla. The blood enters through the paracortex which is also the region which is high in T-
cells 101,102 
 
2.3.2 B-cell abnormalities  
 
Abnormalities in B-cell development can lead to autoimmune diseases, leukaemia or 
lymphomas. B cell malignancies can arise at different stages of the b-cell development. This 
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gives rise to a range of malignancies with a variety of morphological and clinical 
presentations. 77 
 
Figure 10: There are a variety of malignancies which can arise from the different B-cell 
developmental stages. Cancers can arise in the bone marrow, spleen or lymph node. The type 
of cancer and the cells that dominate in each type is based on the area in which the cancer 
formed.78  
 
2.3.3 Lymphoma 
 
Lymphoma is the most common blood malignancy which was  discovered in 1832 by Thomas 
Hodgkin’s, 42 This tumour is characterised by an uncontrollable growth of lymphocytes.66 The 
development of lymphomas is largely unknown, however, the interaction between the 
environment factors and the host is said to play a role in its development.43 In 2012 lymphoma 
developed in 450,000 worldwide with 44% resulting in death ranking it the 7th most common 
cancer in the world.67 79 
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2.3.3.1 Symptoms 
 
The symptoms associated with lymphoma are the same for both Hodgkin’s and non-Hodgkin’s 
lymphomas. The symptoms may include sudden weight loss, night sweats, fatigue, enlarged 
painless nodes, loss of appetite and fever.44 In DLBCL systemic B symtoms (fever, night sweats, 
weight-loss) is seen in 30% of cases and has also been assoiciated with a poor prognosis.68 
 
2.3.3.2 Types 
 
Lymphomas can be divided into 2 subtypes; Hodgkin’s lymphoma (HL) and non-Hodgkin’s 
lymphoma (NHL).37, 44, 45 
 
 In the United States of America, there are an estimated 761,600 people in remission or living 
with lymphoma, where NHL cases are estimated at 584,100.46 The reported survival rate is 
71.4% in NHL and 87.7% in HL. In the United States, approximately 20,000 people die from 
lymphoma every year; 6% from HL and 94% from NHL.46 
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Figure 11: WHO classification of the mature B-cell, T-cell, and NK-cell neoplasms.47  
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2.3.3.2.1 Hodgkin’s 
 
HL is the rarer of the two, where the malignant cells arise from the B lymphocytes.48 Reed-
Sternberg cells are seen in HL, and this is a diagnostic factor that helps distinguish the 
lymphomas. Both lymphomas that have spread and are in situ can be cured.48  
 
2.3.3.2.2 Non-Hodgkin’s lymphoma  
 
NHL is a group of heterogeneous diseases, which originates in the B-, T-, or natural killer (NK) 
lymphocytes. Between 85% and 90% of these lymphoproliferative disorders originate from B 
lymphocytes where the remaining disorders arise from T lymphocytes or NK lymphocytes.45 
There are two clinical categories: indolent, which shows fewer symptoms and slower growth, 
and aggressive, which has fast growth.46  
 
2.3.3.2.2.1 Diffuse large B cell lymphoma 
 
DLBCL is one of the most frequent lymphoma seen. Studies by Perry et al. collected data 
from 1985 to 1999 and from the 487 samples collected 38.2% was DLBCL86,87. Anderson et al., 
collected a total of 1378 samples and looked at Non-Hodgkin’s lymphoma in a variety of 
locations including Hong Kong, Cape Town, Vancouver, London, Lyon, Gottingen, Locarno 
and Omaha.  In London, Vancouver, Omaha and Cape Town there were slightly more 
follicular lymphoma cases than DLBCL but in all other locations DLBCL had the highest 
numbers. In all locations, the percentage of DLBCL was more than 25%.89  
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Diffuse large B cell lymphoma (DLBCL) is one of the non-Hodgkin’s lymphomas which tends 
to be very aggressive.66 It is a clinically heterogeneous disease that presents itself at different 
anatomical sites. There are two subtypes for DLBCL: germinal B-cell-like (GCB) and activated 
B-cell-like (ABC).50, 36, 3  GCB DLBCL has a better prognosis than ABC DLBCL.80 
 
The WHO’s classification system defines 14 subtypes, each of which can be differentiated 
based on the location of the tumour, the presence of other cells within the tumour (such as T 
cells), and whether the patient has certain other illnesses related to DLBCL. One of these well-
defined groupings of particular note is primary mediastinal (thymic) large B cell lymphoma, 
which arises within the thymus or mediastinal lymph nodes.51  
 
In some cases, a tumour may share many features with both DLBCL and Burkitt's lymphoma. 
In these situations, the tumour is classified as simply “B-cell lymphoma, unclassifiable, with 
features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma”. A 
similar situation can arise between DLBCL and Hodgkin's lymphoma; the tumour is then 
classified as “B-cell lymphoma, unclassifiable, with features intermediate between diffuse 
large B-cell lymphoma and Hodgkin’s lymphoma”.47 
 
When a case of DLBCL does not conform to any of these subtypes, and is also not considered 
unclassifiable, then it is classified as “diffuse large B-cell lymphoma, not otherwise specified” 
(DLBCL, NOS). The majority of DLBCL cases fall into this category.47 
 
GCB DLBCL and non-GCB DLBCL 
The subtypes are believed to arise due to the different stages of the lymphoid differentiation. 
In the initial stage of differentiation, the precursor B-cell develops into a naïve B-cell in the 
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peripheral lymphoid tissue. Once the naïve B-cell enters the primary follicle, a germinal 
centre (GC) is formed, where it matures to a centroblast expressing CD10- and BCL6-. The 
centroblast will then later mature further into a plasma-cell or memory b-cell. For further 
maturation to occur a slight downregulation of BCL6- by the MUM1 protein may occur. 76 77 
 
2.3.3.2.2.1.1 Risk Factors 
 
The risk factors associated with the development of lymphoma include several immune 
deficiency disorders. Some of these include HIV infection, ataxia telangiectasia and Wicott-
Aldrich syndrome.51, 76 Some viral, as well as bacterial infections, have been linked to increased 
incidences. Organ transplants have also shown to increase the risk of developing DLBCL by 
10-100-fold.51  
 
There are a number of risk factors that are directly linked to the prognosis. These include the 
age group above 60 years, and having more than one extranodal involvement. The International 
Prognostic Index of risk factors illustrates the profound effect on mortality and survival rates 
(see Figure 12).53  
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Figure 12: Relationship between the survival and mortality based on the International 
Prognostic Index risk factors.49  
 
HIV/AIDS increases the chance of the development of lymphoma by 100 times. It is believed 
that the drop in CD4 count due to HIV infection increases the risk of developing lymphoma, 
especially DLBCL.54 HIV- related lymphomas (HRL) are more aggressive than Non-HIV-
related lymphomas. In addition, they have a shorter life expectancy. However, since the HIV 
treatment regimen (ARVs) has become available to more people, life expectancy has increased 
in these individuals.55, 54  
 
2.3.3.2.2.1.2 Diagnosis 
 
The diagnostic process includes a physical examination to check for enlarged lymph nodes and 
blood tests (including full blood count, LDH). A fine needle aspiration (FNA) can be done on 
enlarged lymph nodes to check for malignant cells if the lymph node is not easily assessable.  
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A biopsy of the lymph node or tissue is done followed by confirmatory immunohistochemistry 
and flow cytometry testing.56 The panel used for immunohistochemistry consists of CD20, CD3, 
CD5, CD10, Bcl-2/Bcl-6, Ki-67, MUM-1 and MYC. The flow cytometry panel used is 
Kappa/lambda, CD45, CD3, CD5, CD19, CD10 and CD20.69 
 
DLBCL is characterized by large abnormal lymphocytes (larger than the normal cells) and the 
fact that the abnormal cells are spread diffusely throughout the tumour. Large lymphoid cells 
that are irregularly shaped with dense chromatin and indistinct nucleoli as illustrated in Figure 
13 is the picture that is seen when DLBCL is present.57  
 
 
 
 
 
 
 
 
Figure 13: Microscopic investigation of DLBC demonstrate large atypical cells, with abundant 
cytoplasm and prominent nucleoli (A), Immunochemistry staining is done to help confirm a 
diagnosis or for subtyping DLBCL cases, B illustrates BCL6+ and C illustrates a BCL6- case.57,100 
 
  
A B C 
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2.3.3.2.2.1.3 Immunohistochemistry and prognosis 
 
Subtyping between GCB and ABC-DLBCL can be done by using different immunochemical 
algorithms. The Hans Algorithm uses three markers to classify diffuse large B cell lymphoma 
from germinal (CD10+, BCL6 +, MUM1-) and non-germinal subtypes (CD10-, MUM1+. 
BCL6-); the Choi algorithm adds two stains, FOXP1, GCET158 and is thought to be more 
accurate at classifying, as well as Muris algorithm which uses BCL2 instead of BCL6. It has 
been shown that the Hans Algorithm is sufficient when investigating prognosis.59  
The study by Amen et al suggested that the expression of Cyclin D2 and BCL2 are the best 
indicators of a bad prognosis .78 In 5% of DLBCL there is chromosomal rearrangements of both 
MYC and BCL2, this is known as a double hit lymphoma (DHL) the prognosis for these patients 
is very poor70 Ki-67 antigen is present in all cycling cells including cancer therefore reflects the 
proliferation rate of the tumour. A study by Broyde et al (2007) suggested a cut-off of 70% 
with a higher expression being indicative of a poor survival.79 
 
2.3.3.2.2.1.4 Cancer staging  
After cancers has been positively diagnosed then cancer is put into different stage based on 
its growth and whether it if has metastasised. Cancer staging is the process of determining 
how far the cancer has developed. There are 4 main stages of DLBCL: stage I and II where a 
group or two or more groups have been affected on only one side of the diaphragm. Stage III 
and IV are regarded as advance stage,  where stage III is where lymph nodes are affected on 
both sides of the diaphragm and stage IV is when lymphoma is outside of the lymphatic 
system.  
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A letter may accompany the number, which is an indication of the presence of B symptoms 
and in the cause of “E” this indicates extranodular involvement. 17, 93, 122 
 
2.3.3.2.2.1.5 Treatments 
 
DLBCL is a curable disease, and  common anthracycline-based chemotherapy is used to treat 
it.60. Rituximab was later discovered and is thought to cause apoptosis and cell death. The 
current treatment regimen of three cycles of CHOP and rituximab is used in conjunction with 
radiation.50, 60 Not all patients with advanced stage DLBCL have been cured by the R-CHOP 
therapy. Therefore, the future therapies may include Bortezomib, Enzastaurin, Lenalidomide, 
and Bevacizumab.50  
 
After treatment, the 5-year survival rate of the subtypes are 60% for GCB and 35% for ABC 
pathway.61  
 
Figure 14: Overall survival rate of DLBCL even with treatment is only 61%.67 
2.3.3.2.2.1.6 MicroRNA in DLBCL 
 
In DLBCL, the level of expression of certain miRNAs can play a major role due to their 
prognostic and diagnostic value.21 Eight miRNAs were found to correlate with overall and 
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event-free survival in DLBCL. These are miR-21, miR-127, miR-34a, miR-195, miR-19A, 
miR-23A, miR-27A and miR-LET7G.31 62 
 
2.4 Biomarkers 
 
Detection, diagnosis, and  prognosis of cancer are just some of the ways in which biomarkers 
have provided to be important in oncology. Biomarkers have also been found to be  useful in 
determining therapeutic intervention in a variety of cancers. Biomarker are simply indicator 
of biological status, originating from within the cell their three main sources are proteins, 
metabolites and nucleic acids. 90 Although biomarkers may not be very helpful when only one 
is used as they lack specificity that links them to one cancer, it is therefore necessary that the 
biomarkers are used as a panel. A panel will then consist of a number of biomarkers that will 
be specific to each cancer, with further testing helping to type cancers and even determine 
prognosis.  
Although there are a number of biomarkers there are three biomarkers that stand out in 
literature when investigating prognosis, BCL2, Ki-67 and BCL6. 78,79,91 
 
2.4.1 BCL6 
 
The zinc finger transcription factor BCL6 proto-oncogene is necessary for germinal centre 
(GC) formation and is found to be frequently translocated in DLBCL..91,93 
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2.4.2 BCL2 
 
Part of the family of apoptotic regulatory proteins BCL2 is an anti-apoptotic protein 
important in normal B-cell development and differentiation. BCL2 is frequently 
overexpressed, GCB the t(14;18) translocation is usually the cause of the upregulation 
whereas in the non-germinal subtype, ABC is overexpressed due to the consecutive activation 
of the NF-κB pathway. 92 
 
2.4.3 Ki67 
 
The nuclear protein Ki67 is used to determine the proliferative activity of the lymphoma by 
determining the number of cell positive for Ki67 and dividing it by the total number of cells. 
Ki67 is expressed by dividing cells throughout the active part of the cell cycle. Ki67 staining 
of about 70% is regarded as having a poor prognosis. 79,91 
 
2.5 HIV and Lymphoma 
 
HIV is classified as a virus called a ‘retrovirus’. It weakens your immune system by 
destroying CD4+ T cell leading to polyclonal proliferation of B cells. The constant 
proliferation then increases the chance of accumulation of mutations.75 
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36.9 million people are currently living with Human Immunodeficiency Virus (HIV) 
worldwide with 67.8% in Sub-Saharan Africa.73,50 According to Shisana et al. (2012) the 
estimated HIV incidence in South Africa increased  to 6.4 million people in 2014, with an 
estimated 321 000 patients diagnosed in the Western Cape.74 HIV infection is an important 
risk factor that has been linked to an increased development of diffuse large B cell lymphoma 
(DLBCL). 
 
2.6 The gap in the research 
 
A higher number of DLBCL cases have been seen within the HIV positive cohort. With the 
high HIV statistics, this has led to an increased risk of developing DLBCL. Although treatable 
HIV-related DLBCL is very aggressive and if not treated may lead to death within a year. 
Research has not yet established whether miRNA-127 expression is lower in a HIV positive 
cohort or whether miRNA-127 remains unaffected, hence not affecting the prognosis.  
 
Our study will investigate the expression of miR-127 in a cohort of HIV-positive and HIV-
negative DLBCL cases. In addition, an investigation of its prognostic potential in HIV positive 
DLBCL will be analysed since no study has determined the relationship in such a cohort.  
 
In 2013, a retrospective study done at Red Cross Children’s Hospital in Cape Town, South 
Africa, over a period of 10 years, showed that 6.5% of HIV-negative children were diagnosed 
with DLBCL whereas children who were HIV-positive, 34.6% DLBCL cases were reported.63  
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There is, however, no information that shows how the HIV status affects the expression levels 
of miR-127 and how this affects the prognosis.  
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MATERIALS AND METHODS 
 
3.1 Ethics Approval 
 
Ethics approval for the project was obtained from the Human Ethics Research Committee, 
Faculty of Health Sciences (HREC REF: 755/2015), at the University of Cape Town. 
 
3.2 Sample size determination 
 
The sample size was determined using the sample size calculation for a qualitative variable.99 
The number of cases selected was based on the prevalence of DLBCL in the population in the 
study by Ferlay75 Other literature was also examined, and the similar sample sizes were used 
in other studies.  
 
3.3 Sample Collection 
 
Cases for this study were selected by initially doing a search on the DISALab system of the 
NHLS to find DLBCL cases submitted for histopathological analysis at the NHLS. The 
Formalin-Fixed Paraffin-embedded (FFPE) tissue was used in our study. The original 
Haematoxylin and Eosin (H&E) stained slides corresponding to the samples were examined 
by a pathologist, from the Division of Anatomical Pathology, NHLS/UCT. Inclusion criteria 
was DLBCL with a population of more than 50% abnormal lymphocytes. The tissue blocks 
of the corresponding cases were then obtained from the archives of the Division of 
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Anatomical Pathology, National Health Services(NHLS), University of Cape Town, Groote 
Schuur Hospital.  
 
3.4 Pathology patient report 
 
Patient reports for the approved cases were accessed from the Department of Radiation 
Oncology at the Groote Schuur Hospital, Cape Town under the supervision of the Head of 
oncology department (Collaborators). The age, stage, serum lactate dehydrogenase levels, 
performance status and involvement of extranodal sites were noted. The date of death (if 
relevant), sex and HIV status were also noted. 
 
3.5 H&E staining 
 
The DLBCL samples were cut into 3µm sections and dewaxed in xylene. The sections were 
dehydrated through a descending series of alcohol followed by being washed under running 
water. The slides were then placed in Meyers Haematoxylin for 5 minutes to stain the nucleus 
before being rinsed and then blued with Ammoniated water for 3 minutes. The slides were 
washed again and put into the counterstain, phloxine Eosin for 15 minutes.  Finally, slides 
were washed, dehydrated through an ascending series of ethanol, cleared in xylene and 
mounted with Entellan .  
 
After staining, slides were then examined and demarcated by a pathologist, thus indicating 
tumour regions. This is done to ensure that no necrotic material or other tissue was scraped, 
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to prevent false readings or contamination. After slides were demarcated, more sections were 
cut at 8µm to be used for the RNA extraction.  
 
 
3.6 RNA Extraction  
 
3.6.1 Tissue Preparation 
 
RNA was extracted from FFPE tissue.  8µm tissue section were cut and placed on glass slides 
and baked on a 60˚C hot plate for an hour to melt the wax. The slides then passed through a 
series of xylene and alcohol washes, to enable dewaxing and clearing respectively. Finally, 
the slides were rinsed well before being left overnight at room temperature to dry.  
When the slides were sufficiently dry they were superimposed onto the demarcated H&E 
slides previously marked by pathologist, to ensure that the correct area is scraped. The tissue 
was then scraped using scalpel blades before being transferred to autoclaved Eppendorf 
tubes. For each case three 8µm sections of tissue was used.  
 
3.6.2 RNA extraction 
 
The High Pure FFPE RNA Micro Kit Version 7 by Roche was used for RNA extraction. The 
protocol provided by Roche was utilised. This started with 60µl tissue lysis buffer and 10µl 
10% Sodium Dodecyl (lauryl) Sulfate (SDS) being added to the scraped tissue. The SDS 
solubilizes the lipids and proteins in the membrane thus exposing the chromosome. 
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30µl Proteinase K was then added followed by spinning and incubating in a water bath at 
55̊͘C for 3 hours. The incubation ensures the proteinase is able to digest the protein and 
remove contamination. After incubation 200µl binding buffer and ethanol were added to the 
eppendorf tube, mixed well with the vortex and spun down. The lysate was then pipetted into 
the top reservoir of the micro filter tubes provided. These tubes ensure that the RNA is 
captured on the filters allowing all debris to pass through and be discarded. 30µl DNase 
solution was added to the dry micro filter tube and was then incubated at room temperature 
for 15 minutes. The filter was then washed 3 times, once using wash buffer I and twice with 
wash buffer II, centrifuging after each addition to ensure clean RNA remains on the filter. 
The High pure micro filter tube was added to a new micro-centrifuge tube before the 20µl 
elution butter was added to help release the RNA from the filter. The flow through was pure 
total RNA.  
 
3.7 RNA quantification and Polyadenylation   
The RNA samples were quantified using a Nanodrop (Thermo Scientific, Wellington, DE 
19810 USA) instrument. Initially 1µl RNAse-free water was used to blank the Nanodrop 
before using a volume of 2µl RNA from the extraction sample for the procedure. 
The concentration of the samples were diluted to 100ng to be used for the addition of the 
Poly A tail. The Poly A reaction was carried out in a final volume of 20µl consisting of 
template RNA (100ng); 5 x PAP buffer; 25mM MnCl2; 100mM ATP; nuclease free water 
and 2U/µl of poly (A) polymerase. A negative control (nuclease free water instead of RNA) 
was included in the reaction. The product was then loaded on to the PCR (GeneAmp PCR 
System 9700, Applied Bioscience). The PCR conditions used were 37°C for 75 minutes and 
65°C for 25 minutes. 
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3.8 cDNA synthesis 
 
Subsequent to the poly A reaction, cDNA was synthesized in a final volume of 20µl using 
100ng Poly A product, dH2O, 10mM dNTPs, 5x transcription reverse transcriptase reaction 
buffer, 25mM MgCl2, 40U/µl protector RNase inhibitor, 20U/µl transcriptor reverse 
transcriptase and 50mM adaptors. The PCR conditions were as follows: 
• 42°C for 60 minutes 
• 42°C for 75 minutes  
• 85°C for 10 minutes 
 The cDNA products were then diluted to 1000ng and stored at -20°C. 
 
 
 
 57 
 
3.9 miRNA- 127 primer design 
 
Primers for miRNA-127 was performed using the method outlined in the study by Balcells, 
Ciera and Busk (2011) where 18S and U6 were used as a housekeeping gene for each sample. 
The primers sequences in table 1 were synthesised in the Department of Molecular cell 
Biology at the University of Cape Town (UCT).  
 
Table 2: Primer set sequences for miR-127 and two references genes used, 18S and U6 
 
 
3.10 Primer Optimization 
 
In order to optimise RT-PCR conditions and to verify the specificity of the primer pair, the 
optimal primer concentration and volume were tested using the KicqStart SYBR Green 
(Sigma Aldrich). The primer titration was preformed using concentrations of the primer 
ranging from .05µm to 300µm for the total reaction volume of 20µl. In all wells 10ul SYBR 
green as well as 3µl cDNA was used, the optimal primer volume was also tested from 
ranging from 0.5µl to 2µl.  
 
Forward primer Reverse primer 
miRNA-127 CGCAGCTGAAGCTCAGA CAGGTCCAGTTTTTTTTTTTTTTTATCA 
18S TTTCGCTCTGGTCCGTCTTG TTCGGAACTGAGGCCATGAT 
U6 CTCGCTTCGGCAGCACA AACGCTTCACGAATTTGCGT 
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3.11 miRNA-127 quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-
PCR)  
 
For each primer, U6, 18s and miRNA-127 a master mix was prepared using 2x Sybrgreen 
(KapaBiosystems), dH2O and 10µM of the primers (Table 2.4) in separate eppendorf tubes. 
The eppendorf tubes were then briefly vortexed and a volume of 19.3µl from each master 
mix was added to 96 well plates, alternating rows between the two primers. 0.7µl cDNA 
(1000ng) from each of the samples was added into the 19.3µl master mix in triplicates. A 
blank (B), in which sterile water was added instead of cDNA was included to normalise the 
reaction. The 96 well plates were then covered with adhesive sealing films to prevent 
evaporation, leakage and contamination between the wells. The plates were then centrifuged 
at high speed and placed in a Light Cycler480® instrument (Roche) to perform the qRT-PCR 
using the conditions below. The qRT-PCR was performed twice to verify the quantitative 
data generated by the instrument. 
Table 3: The qRT-PCR process  
Stage Number of cycles Temperature (°C) Time  Ramp (°C/s) 
Pre-incubation 1 cycle 95 5 m 4.4 
Amplification 45 cycles 95 (Denaturation) 10s 4.4 
60 (Annealing) 15s 2.2 
Melting curve 1 cycle 95 5s 4.4 
65 1s 2.2 
97 Continuous 0.11 
Cooling 1 cycle 40 30s 2.2 
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3.12 Statistical analysis  
 
The expression patterns of miR-127 were compared to the clinicopathological features using 
Chi-square test. A p value of ≤ 0.05 indicated statistical significance.  
 
3.13 Relative Quantification 
 
Expression levels of miR-127 relative to 18s and U6, the reference genes, in each sample 
were determined by dividing the absolute concentration of the target gene by the absolute 
concentration of the housekeeping gene. The resulting ratio expressed the amount of target 
relative to the reference gene in each sample.  
 
The fold change can then be determined by using an experimental sample with lower 
normalization value as the calibrator.  Each normalized value is divided by the calibrator to 
determine the fold change. 
 
The calculation used in the study by Robertus et al.,34 was also used to compare the results 
obtain against their findings. In their study they used the U6 as a reference gene. They 
normalized the target miRNA relative to the reference gene using the following formula: 
∆Ct = (∆Ct miRNA-127 – ∆Ct U6). Relative expression levels were expressed as 2-∆Ct.  
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3.14 Immunohistochemistry method and evaluation  
 
All staining is done using thin FFPE tissue  sections of 3µm. The sections first undergo 
antigen unmasking to help the antibody binding site to be revealed. The stains have labelled 
antibodies that will bind to their respective antigen and therefore stain positive.  
For the evaluation of the three biomarkers that were used, BCL6, BCL2 and Ki67, 
immunohistochemical staining results from the patient file was used, where available. BCL6 
and BCL2 are done in the lab to help classify DLBCL into GCB and ABC, which may help 
with treatment. In the case of Ki67, the cell proliferation marker, a highly statin tissue is said 
to be more aggressive. Ki67 is also used routinely to determine treatment efficacy where high 
percentage reflect worse outcome.  
When making the diagnosis, the percentage of positively stained cells  are scored.  
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CHAPTER 4: RESULTS 
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RESULTS 
 
4.1. The clinicopathologic/demographic features of all the DLBCL cases 
 
A total of 42 DLBCL cases were enrolled in the study (appendix A). There were more 
females (57%) than males. The ages ranged from 15 years to 90 years, with the majority of 
cases being over 60 years. For the 42 cases the mean age of the patients was 50, although 
HIV positive DLBCL cases had a lower age average (37 years) and HIV negative cases had 
an age average of 60 years old. There were 10 HIV positive cases and 30 HIV-negative cases, 
and 2 cases had no HIV status recorded.  
 
Furthermore, 22% cases presented with stage I, 19% with stage II, 16% with stage III and 
only 44% presented with stage IV of the tumour, but 10 cases were undefined. There were 11 
cases which presented with extranodal involvement, but 17 cases had no record, whether 
there was involvement or not, 33% of cases were cervical lymph nodes, with the sites ranging 
from inguinal node to axillary node.  
Only 14 patients out of 42 had been recorded as deceased, with the majority occurring as a 
result of cancer related problems (Table 4).  
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Table 4: The clinicopathologic features of the 42 cases 
Clinicopathologic features  Number of cases with valid entry 
Age <60 = 23 
>60 =19 
Sex Ratio (M: F) 18:24 
Ann Arbour Stage I = 7 
II =6 
III =5 
IV =14 
Not recorded = 10 
Extranodal involvement Involved = 11 
Not Involved =14 
Not recorded = 17 
HIV cases HIV positive = 10 
HIV negative = 30 
Deceased patients 14 
GCB/ABC GCB = 14 
ABC =16 
NR=10 
Cervical node 14 
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Figure 15: The distribution of gender in the DLBCL cohort 
 
Figure 16: The relationship between gender in the distribution of site of cancer in the DLBCL 
cohort  
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Figure 17: The relationship between gender and extranodal involvement  
 
 
Figure 18: The relation between gender in the distribution of age in the DLBCL cohort 
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Figure 19: The relation between gender in the distribution of stage of cancer in the DLBCL 
cohort 
 
Figure 20: The relation between gender in the distribution of subtype in the DLBCL cohort. 
*(GCB – Germinal Centre B-cell. ABC – Activated B-cell)  
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4.2 Comparison of HIV positive vs HIV negative cases 
 
Table 5: Comparison of the clinicopathologic features and HIV status 
 HIV- DLBCL HIV+ DLBCL No record  
Number of cases 30 10 2 
Age Range 28-90 15-63  
Age average 60 37  
Ann Arbor Stage   11 (2) 
I 6 1  
II 3 3  
III 3 1  
IV 11 3  
Elevated LDH 
(>480=U/L) 
14 6 11 (3) 
ECOG Performance 
status 
  18 (5) 
0 2 0  
1 7 2  
2 3 1  
3 6 2  
4 1 0  
Site   18 (4) 
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Nodal 8 5  
Extranodal 10 1  
Subtype   10(2) 
GCB 10 4  
ABC 11 5  
IPI (≥3) * 14 2  
*IPI was determined only for cases that had record of all five factors 
There were 31 and 24 cases with Ann Arbor stage and performance status (PS) 
recorded, respectively (Table 5). The majority of the HIV negative cases were 
classified as stage IV (47.8%). In contrast, the majority of cases in the HIV positive group 
were classified as stage II and stage IV (37.5%).  
There were 16 cases with IPI more or equal to 3 recorded, of which only 2 were HIV 
positive.  
 
Just 57% of all DLBCL cases had record of nodal involvement, where 54% were nodal 
lymphomas. 55% of HIV negative cases were recorded as having extranodal involvement, in 
contrast to the HIV positive cases being only16.6%.  
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Figure 21: The relation between gender and HIV status in the DLBCL cohort 
 
 
Figure 22: The relation between HIV status and DLBCL subtype in the DLBCL cohort 
*(GCB – Germinal Centre B-cell, ABC – Activated B-cell)  
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4.3 Comparisons of HIV status and immunohistochemical stains 
 
Table 6: Comparison of the immunohistochemistry stains and HIV status 
IMMUNOHISTOCHEMICAL STAIN HIV- DLBCL HIV+ DLBCL Cases with no data 
BCL2 positive (Total) 18 (25) 5 (6) 11 
BCL6 positive (Total)  22 (29) 7(10) 3 
KI67 ≥70% (Total) 16 (22) 7 (7) 13 
   
Only 74% and 69% of DLBCL cases had BCL2 Ki67 recorded respectively, whereas 93% of 
cases had BCL6 results. All HIV positive cases had a Ki67 results higher have 70%, where 
HIV negative had only72.7% cases that were higher than 70%. 83% of HIV positive cases 
were possible for BCL2 in contrast to the 72% HIV negative cases. The BCL6 results were 
closers, with 76% positive cases for HIV negative cases and 70%postive cases for HIV 
positive cases.  
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Figure 23: The relation between HIV status and the positive immunohistochemistry staining 
in the DLBCL cohort 
 
4.4 MiRNA-127 expression levels 
 
73.8% of the DLBCL cases had higher miR-127 expression levels than the normal and 
reference genes. 41.9% of cases are over 60 years old and 57.8% HIV-negative. Disregarding 
the cases without staining data, 75% of cases were BCL6 positive, 76.2% BCL2 positive and 
73.7% had a Ki67 above 70%. 35.5% of cases were patients whom had died within a year of 
diagnosis. 
 
26.2% of DLBCL cases recorded no miR-127 expression level and was regarded as being 
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had Ki67 percentages greater than 70% and all but 3 had positive BCL6. It should be noted 
that the 3 cases which were BCL6 negative were all BCL2 positive. Although there was one 
case that had no BCL2, out of the remaining cases only 30% of cases were BCL2 negative 
and all these cases were BCL6 positive. Only 27.2% of cases were cases where patients had 
died within a year of diagnosis.  
 
Table 7: Comparison of the clinicopathologic features and miR-127 expression levels 
VARIABLE MiRNA-127 EXPRESSION 
High Expression Silenced Not recorded  
Sex (F:M) 17:14 7:4 0 
Age    0 
Above 60 13 5  
Ann Arbor Stage   11 
I 6 2  
II 4 2  
III 3 1  
IV 9 4  
Elevated LDH (>480=U/L) 13 7 11 
ECOG Performance status   18 
0 1 1  
1 7 2  
2 4 0  
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3 6 2  
4 1 0  
Nodular Involvement   18 
Nodal 11 2  
Extranodal 8 3  
Subtype   11 
GCB 9 5  
ABC 12 4  
IPI (≥3) 12 4 3 
Positive Immuno stains    
BCL6 21 8 3 
BCL2 16 7 11 
Ki67 (≥70%) 14 8 13 
HIV Status   2 
Positive 6 4  
Negative 23 7  
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Figure 24: The relation between gender and expression levels of miR-127 the DLBCL cohort 
 
Figure 25: The relation between HIV status and expression levels of miR-127 the DLBCL 
cohort 
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Figure 26: The relation between positive immunohistochemical stains and expression levels 
of miR-127 the DLBCL cohort 
 
4.5 Significance of clinicopathological feature in association with miRNA-127 expression 
 
Out of the cases used 73.8% had higher expression levels than that of the normal tissue and 
that of the reference genes, and 26.2% were silenced. However, there is no statistical 
significance of any of the clinical feature in respect to the expression levels of miRNA-127. 
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Table 8: Significance of the clinicopathologic features and expression of miRNA-127 
Clinical Feature Significance in respect to miRNA-127 
Sex Not significant (p=0.796) 
Age (Above 60)  Not significant(p=1) 
Subtype  Not significant(p=0.311) 
HIV status Not significant(p=0.417) 
BCL6 positive Not significant(p=0.322) 
BCL2 positive  Not significant(p=0.498) 
Ki67 above 70% Not significant (p=0.546) 
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CHAPTER 5: DISCUSSION AND CONCLUSION 
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DISCUSSION 
The expression levels of miR-127 were correlated to clinicopathological features thought to 
be important for prognosis, as well as factors on the International Prognostic Index (IPI). 
These factors included age, Lactate Dehydrogenase levels, Performance status, stage of 
cancer and extranodal involvement. We also correlated the expression levels with HIV status, 
sex, survival status and three immunohistochemical stains thought to have prognostic value.  
 
DLCBL is a curable disease but if left untreated leads to death within a year of diagnosis.46 
Lower expression levels of miR-127 has also been associated with a bad prognosis and it was 
therefore important to determine which factor are significant to the expression levels of miR-
127, if any.  
 
Regarding gender distribution, we found that the majority of the cohort were female (57%) 
whilst the males were the minority (18/42). Studies by Sarkozy et al.,104 Hasselblom et al.,105 and 
Robertus et al.,32 all demonstrated a different relationship with the majority of case being male 
in these studies. These studies correlate with the Ferlay global statistics where there are a 
higher number of males diagnosed with non-Hodgkin’s lymphomas. 75This may well be due to 
the smaller sample size but could also be due to the difference in the epidemiology in the 
studies. However, there was a study done by Pinnark et al.,113 that did have a cohort similar to 
our study with the female patients being 59.1%. 
 
Regarding the age range, the majority of female cases ages were concentrated above the age 
of 60. In contrast, the male DLBCL were had more than 50% of their cases under the age of 
40 which is similar to other published data. A study by Hedström et al., 106 found that the male 
cohort was more at risk of developing DLBCL when under 50 as opposed to the female 
 79 
 
cohort who only were at higher risk after the age of 60. Even in a much younger cohort as 
seen in the study by Burkhardt et al., the older the female patients were still at higher risk 
than the younger patinets.107 In the study by Beheshti et al., the older female group were found 
to have less DLBCL progression when compared to younger female group and to males. 
They found that the JUN signalling was linked to the age, and CYCS signalling pathway was 
linked to the differences in gender. 109,110 
 
In our study there was no significance association found between gender, overall survival and 
progression free survival.  
 
In our study, gender and age was compared to the site of the DLBCL, there was no difference 
in cervical lymph nodes (33%) based on gender.  When the extranodal involvement was 
investigated it was established that 26.2% of cases had extranodal involvement of 
which16.7% was male. In our study there was no significance association with extranodal 
involvement. In a study by Yao et al.,111 however, it was shown that the extranodal 
involvement was associated with a worse prognosis of which 58% of the extranodal cases 
were males. 
 
In the study by Robertus et al.,31 they were able to establish that the expression of miR-127 
was linked with the site of presentation, as the testicular DLBCL had much higher expression 
than the CNS DLBCL presentation.  
 
 The study by Cote et al.,117 demonstrated that HIV increased the risk of developing DLBCL 
by more than 150-fold, making HIV status an important factor to investigate when looking at 
prognosis.  Regarding the HIV status, our study had a higher number of HIV negative cases 
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(71.4%) to that of Pinnark et al.,113 who had 93.7% HIV negative cases. In a comparison 
between the HIV-positive and HIV-negative DLBCL cohorts there were higher number of 
females in the HIV-positive cohort in comparison with males. However, in the HIV-negative 
cohort there were also more females. So, there was no correlation made between HIV status 
and sex nor was a relationship establish on how they relate to the miR-127 expression. The 
fact that the groups (sex and HIV status) were not equally represented made it difficult to 
determine if there was any correlation between them. In addition, there is a higher number of 
females in the HIV positive cohort, this is in line with literature which showed the higher 
proportion of females infected with HIV in South Africa.73,74  
 
In addition, we were also unable to observe any relationship between IPI, stage, age and 
performance status between the HIV negative and positive DLBCL groups. This is in contrast 
to the study by Baptista et al.,102 which indicated that HIV-positive cases were more inclined 
to have higher performance status, later staging and a worst overall survival rate. Coutinho et 
al.,115 showed that HIV positive patients had significantly longer disease-free state and overall 
survival than the HIV negative cohort. 
 
Overall the expected outcome was a lower expression of miR-127 in all the DLBCL cases 
with a marked decreased in the HIV positive cases. Although no other literature showed the 
relationship between HIV-positive cases and low miR-127 expression in DLBCL, it was 
expected that HIV positive cases may have a lower expression or may even be silenced. In 
addition, it was expected that factors on the IPI may also be associated with lower expression. 
This was however not the case as only 40% of HIV positive cases were silenced. Overall only 
26.2% of cases were silenced and the other 73.8% had higher expression levels than the 
normal sample ranges.  
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 Another factor investigated for prognostic value was the subtyping found in DLBCL, 
germinal centre B-cell (GCB) and activated B-cell (ABC). In our study 12 cases could not be 
subtyped but of the rest, 46.7% were GCB and 53.3% were ABC DLBCL. Although the 
studies by Nowakowski and Czuczman 119 and by Frick et al., 120were able to establish a 
relationship between subtype and prognosis, concluding that ABC DLBCL had a worse 
prognosis than GCB DLBCL. However, we were unable to prove such a relationship. Chen et 
al.,112 were also able to support the finding by Frick et al.,120 and were able to further 
demonstrate that there was a relationship between extranodal involvement and subtype; as 
well as stage and LDH. In their study, they had majority GCB DLBCL and majority males. 
84.6% of the GCB DLBCL cases had extranodal involvement and 84.2% of ABC DLBCL 
cases had extranodal involvement. With more than half (61.5%) of GCB cases being stage 3 
and 4 DLBCL, and 81.3% of ABC cases were stage 3 and 4.  
   
The prognostic value BCL6, BCL2 and Ki67. When the stain profile was correlated with 
miR-127 expression in our cohort of 42 DLBCL cases all but 10 of our cases had a higher 
expression levels of miR-127. These 10 cases were silenced but had no significant 
clinicopathological feature. In the 10 cases all but 3 cases had positive BCL2 immunostaining 
and were above 70% for Ki67. This was also seen to be the case in the study by Iqbal et al., 
where BCL2 had no significance in prognosis of DLBCL and although other studies noticed a 
relationship between deceased overall survival and BCL2 there was no true significance.94, 108 
However the study by Pather et al., 114 did determine that in the case of GCB DLBCL BCL2 
positivity was indicative of an improved survival. 
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Xie et al.,116 determined that KI67 should be regarded as an important indicator of prognosis 
stating that its presence was associated with a poor prognosis as they showed there was a 
relationship between LDH, stage and age.  
 
In our study we determined that BCL6 had not significant prognostic value, as only 25% had 
been silenced which was similar to the study by Kawamoto et al.,118 who also showed that 
BCL6 had no significant relationship with overall survival. However, the study by Lossos et 
al95 demonstrated a relationship between BCL6 and overall survival, deeming the presence of 
BCL6 as an indicator of a good prognosis.  
 
Our study included reactive nodes to compare the expression level of miRNA-127, all these 
cases had an elevated miRNA-127 expression level. Although less than half of the group 
were HIV-positive, all miRNA-127 expression levels were high with a higher average 
expression than the HIV negative DLBCL cases. In some of these cases the expression levels 
were two-fold higher than that of the normal patient sample. The chip by Qiagen had also 
shown an upregulated miRNA-127 expression in our DLBCL cohort when the samples were 
pooled, which then supported our results using a different method. 
 
The correlation between clinicopathological features and the miRNA-127 expression levels 
showed that there was no significant association with age, staging, sex and serum LDH which 
was in keeping with other published literature.,29.96 We were also unable to establish any 
statistical significance relationship between miRNA-127 expression and HIV status.  
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CONCLUSION 
To our knowledge this was the first study that investigated the correlation between miRNA-
127 and HIV status in a cohort of DLBCL using FFPE tissue in the South African cohort.  
There were seven factors that were investigated for prognostic value, age, gender, HIV status, 
Ki67, BCL6, BCL2 and miRNA-127 expression levels.  
 
For age 45% of cases were above the age of 60, where it was expected to be more than 50%. 
Regarding gender there was a female to male ratio (female:male) was 4:3. There was no 
marked difference so we were unable to establish a clear prognostic value. The majority of 
the cases were HIV negative with the ratio to positive cases at 3:1(negative: positive). This 
was expected to be the other way around, as there has been in increased number of DLBCL 
cases as HIV cases has increased. 54 The immunostaining results had a bigger difference 
margin than the above mentioned factors, with Ki67 86% of cases had a high Ki67 
percentage. The BCL2 had 74% positive cases and BCL6 had 70% positive cases. Regarding 
the miRNA-127 expression there were only 26% of cases that were silenced where 74% had 
a higher expression than the normal range. When comparing the cases with silenced miRNA-
127 expression and immunostaining results, Ki67 and BCL6 stained positive for all the cases 
expect 3 cases for BCL6 and 1 case in Ki67.  
 
In conclusion we found no correlation between miRNA-127 expression and the possible 
prognostic biomarkers but Ki67 used in conjuction with BCL6 could be good biomarkers to 
use as almost all cases that were silenced were positive for BCL6 and Ki67.  
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Regarding future approaches the biggest hurdle encountered in our study was the distribution 
of not only sex but also HIV status.  It would therefore be good to open up the time period 
from which samples can be taken to ensure that an equal number of men and women that are 
HIV positive and HIV negative with DLBCL are obtained. It would also be beneficial to look 
at the studies that have all the information (biomarkers) recorded to help determine if there is 
a relationship.  
 
 It would also be interesting to investigate  reactive nodes,  as all the reactive nodes had a 
higher expression level of miRNA-127 than the normal range  
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APPENDIX 
 
Appendix A: Staging of Cancer 
There are 4 main stages of DLBCL: 
• Stage I: 1 group of lymph nodes affected 
• stage II: 2 or more groups of lymph nodes affected, above or below the diaphragm  
• stage III: lymph nodes affected on both sides of the diaphragm 
• stage IV: lymphoma is found in organs outside the lymphatic system or in 
the bone marrow. 
A letter may accompany the number.  
• A: no B symptoms 
• B: B symptoms present (fever, night sweats, weight loss) 
• E: extranodal lymphoma (outside of the lymph nodes). 
Stage 1A and stage 2A referred to as ‘early-stage’ DLBCL. ‘Advanced-stage’ DLBCL is 
stage 3 and stage 4.  
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Appendix B: The clinicopathologic data of 42 cases of DLBCL 
 
Case # 
Age 
(Y) Gender Grade 
Lymph 
nodes Stage 
HIV 
status 
GC/non-
GG 
1 65 Female 1 Yes IV Left Distal 
2 35 Female 3 No II Left Distal 
3 57 Female 1 Yes III Left Distal 
4 32 Female 1 Yes III Left Distal 
5 60 Female 3 Yes III Right Proximal 
6 56 Male 2 No I Right Proximal 
7 42 Male 1 No I Right Proximal 
8 62 Female 1 No III Left Distal 
9 51 Female 2 No I Left Distal 
10 83 Male 1 No III Left Distal 
11 65 Male 1 Yes IV Left Distal 
12 59 Male 2 Yes III Right Proximal 
13 65 Male 3 Yes III Right Proximal 
14 70 Female 2 Yes I Left Distal 
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15 68 Male 2 No II Right Proximal 
16 51 Male 2 Yes III Left Distal 
17 52 Female 2 Yes III Left Distal 
18 50 Male 2 No I Left Distal 
19 72 Female 3 Yes III Right Proximal 
20 58 Male 2 No I Left Distal 
21 75 Female 1 No II Left Distal 
22 74 Male 2 No III Right Proximal 
23 50 Male 2 No III Left Distal 
24 59 Female 2 No I Right Proximal 
25 65 Female 2 No I Left Distal 
26 61 Female 2 No I Right Proximal 
27 51 Female 2 No IV Left Distal 
28 63 Female 2 No III Right Proximal 
29 60 Female 2 No I Left Distal 
30 70 Male 2 No III Right Proximal 
31 64 Male 2 No III Left Distal 
32 65 Male 2 No III Left Distal 
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33 80 Male 2 No I Left Distal 
34 77 Male 2 No I Right Proximal 
35 55 Male 2 Yes III Left Distal 
36 60 Female 2 Yes IV Right Proximal 
37 73 Male 2 No II Right Proximal 
38 84 Female 2 No III Left Distal 
39 40 Male 2 No I Right Proximal 
40 30 Female 2 No I Right Proximal 
41 76 Female 2 No III Right Proximal 
 
  
 106 
 
Appendix C: DLBCL classification types using immunohistochemistry stains 
 
There are a number of algorithms that can be used to determine the subtype of DLBCL. For 
the purposes of my study the Hans’ Algorithm is sufficient and was used to subtype DLBCL 
cases.95  
 
 
 
 
